Skip to content

Antibiotic pharmacokinetics in women with twin pregnancy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518564-12-00
Enrollment
92
Registered
2024-12-11
Start date
2023-01-05
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Brief summary

Pharmacokinetic: Differences in antibiotic concentration between twin pairs, Antibiotic cord/maternal ratio, The maternal antibiotic volume of distribution (Vd), clearance (Cl), Protein binding (PB), Placenta interstitial fluid concentration, Umbilical cord antibiotic concentration

Detailed description

Clinical descriptive endpoints: Maternal postoperative infection or sepsis, Early-onset neonatal sepsis., Safety endpoints: Safety and tolerability of the antibiotics will be collected to define any adverse drug reaction (clinically observed, haematological or biochemical) that is reported by the clinical staff that is suspected as being caused by any of the study antibiotics., Substudy endpoints: Differences in antibiotic concentration between monochorionic and dichorionic twin pairs

Interventions

DRUGStandacillin 2 g – Pulver zur Herstellung einer Injektions-/Infusionslösung
DRUGDalacin C® Phosphat 600 mg/4 ml – Ampulle
DRUGPiperacillin/Tazobactam Sandoz 4
DRUG0 g/0
DRUG5 g - Pulver zur Herstellung einer Infusionslösung

Sponsors

Medical University Of Vienna
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic: Differences in antibiotic concentration between twin pairs, Antibiotic cord/maternal ratio, The maternal antibiotic volume of distribution (Vd), clearance (Cl), Protein binding (PB), Placenta interstitial fluid concentration, Umbilical cord antibiotic concentration

Secondary

MeasureTime frame
Clinical descriptive endpoints: Maternal postoperative infection or sepsis, Early-onset neonatal sepsis., Safety endpoints: Safety and tolerability of the antibiotics will be collected to define any adverse drug reaction (clinically observed, haematological or biochemical) that is reported by the clinical staff that is suspected as being caused by any of the study antibiotics., Substudy endpoints: Differences in antibiotic concentration between monochorionic and dichorionic twin pairs

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026